- Home
- HOWL vs ICCC Comparison
HOWL vs ICCC Comparison
Compare HOWL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- ICCC
- Stock Information
- Founded
- HOWL 2017
- ICCC 1982
- Country
- HOWL United States
- ICCC United States
- Employees
- HOWL N/A
- ICCC N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- ICCC Health Care
- Exchange
- HOWL Nasdaq
- ICCC Nasdaq
- Market Cap
- HOWL 64.5M
- ICCC 55.5M
- IPO Year
- HOWL 2021
- ICCC 1987
- Fundamental
- Price
- HOWL $1.22
- ICCC $6.30
- Analyst Decision
- HOWL Strong Buy
- ICCC
- Analyst Count
- HOWL 5
- ICCC 0
- Target Price
- HOWL $7.20
- ICCC N/A
- AVG Volume (30 Days)
- HOWL 891.7K
- ICCC 21.7K
- Earning Date
- HOWL 11-04-2025
- ICCC 11-13-2025
- Dividend Yield
- HOWL N/A
- ICCC N/A
- EPS Growth
- HOWL N/A
- ICCC N/A
- EPS
- HOWL N/A
- ICCC 0.20
- Revenue
- HOWL N/A
- ICCC $28,274,756.00
- Revenue This Year
- HOWL N/A
- ICCC N/A
- Revenue Next Year
- HOWL N/A
- ICCC N/A
- P/E Ratio
- HOWL N/A
- ICCC $31.40
- Revenue Growth
- HOWL N/A
- ICCC 21.75
- 52 Week Low
- HOWL $0.60
- ICCC $3.38
- 52 Week High
- HOWL $2.52
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- HOWL 33.34
- ICCC 51.36
- Support Level
- HOWL $1.16
- ICCC $5.90
- Resistance Level
- HOWL $1.83
- ICCC $6.28
- Average True Range (ATR)
- HOWL 0.14
- ICCC 0.29
- MACD
- HOWL -0.06
- ICCC -0.01
- Stochastic Oscillator
- HOWL 18.67
- ICCC 47.67
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.